Human Milk Oligosaccharides Market Report 2026-2036: High-Value Insights for Strategy, Product Development & Growth Planning

The global human milk oligosaccharides market is poised for robust growth, projected to expand from USD 101.1 million in 2025 to USD 191.6 million by 2035, reflecting a CAGR of 6.6% over the forecast period. Rising awareness of HMOs' benefits in early childhood nutrition, advancements in synthetic biology, and increasing inclusion in infant formula, functional foods, and dietary supplements are fueling this growth.

HMOs are gaining traction not only for their prebiotic and immune-boosting properties but also for emerging applications in adult health. Research highlights their role in long-term immune system modulation and gut-brain axis regulation, broadening their adoption across pediatric and adult nutrition markets.

Get Exclusive Access To Data Tables, Market Sizing Dashboards, And Analyst Insights. Request Sample Report! https://www.futuremarketinsights.com/reports/sample/rep-gb-4252

The market is witnessing strong momentum thanks to growing investments in HMO research, clinical validation, and supportive regulatory frameworks. Key HMOs, including 2'-FL, 3-FL, and LNnT, are being scaled up for production globally, ensuring wider availability and consistent quality.

Market Insights and Segmentation

• Leading Application Segment (2025): Infant Formula - 60% share
• Leading Product Segment: Fucosylated HMOs - 35% share
• Key Growth Region: Asia-Pacific (India, China, UK)
• Top Players: Chr. Hansen (Jennewein Biotechnologie), BASF, FrieslandCampina Ingredients, Abbott Nutrition, dsm-firmenich (Glycom)

HMOs represent approximately 50-55% of the infant formula ingredients market, mimicking the benefits of breast milk. In functional foods and beverages, they hold 3-5%, while in nutraceutical ingredients and prebiotics, their shares are 2-3% and 10-15%, respectively. Specialty sugars and biotechnology ingredients account for 1-2% of the HMO market, reflecting their high-value, bioengineered origins.

Recent innovations include plant-based HMO production using genetically engineered Nicotiana benthamiana, offering a sustainable and economically viable approach to large-scale synthesis of fucosylated, acidic, and neutral HMOs.

Semi-Annual Market Trends

• H1 2025-2035 CAGR: 6.5%
• H2 2025-2035 CAGR: 6.8%

This semi-annual analysis indicates a slight decrease in growth in the first half of 2025 followed by acceleration in H2, reflecting market stabilization and increased production efficiency.

Investment Focus: Key HMO Segments

Fucosylated HMOs are expected to secure a 35% market share by 2025 due to their critical role in immunity and gut health. Precision fermentation technologies are enabling commercial-scale production of 2ʹ-Fucosyllactose and related trisaccharides, providing benefits such as selective nourishment of beneficial Bifidobacterium species and pathogen inhibition.

Infant formula remains the dominant application, capturing 60% of the market, driven by growing demand for advanced breast milk alternatives. Multi-HMO blends like 2ʹ-Fucosyllactose and Lacto-N-neotetraose are increasingly incorporated to support immune, gut, and cognitive development.

• Asia-Pacific: Rapid premiumization, higher birth rates, and consumer willingness to invest in quality nutrition are driving growth.
• Europe and North America: Biotechnology collaborations and expanded production capacity ensure cost-efficient and reliable HMO supply.

Clinical studies in Spain, China, and across Europe reinforce HMO supplementation benefits, including improved cognitive function, gut health, and immune support in toddlers and infants.

Expanding HMO Applications

• Gut-Brain Axis Integration: HMOs are now being explored for their influence on neurodevelopment, stress response, and cognitive function, leading to multi-HMO formulations targeting brain health.
• Fermentation-Based Production: Microbial fermentation is improving cost efficiency and purity, making HMOs accessible for mid-tier brands and functional food applications.
• Regulatory Recognition: GRAS approvals and regulatory support in North America, Europe, and Asia-Pacific are facilitating global HMO adoption.

Country-Wise Insights

• USA: Growing functional beverage sector with HMO-infused RTD drinks and immune-boosting shakes. CAGR: 4.8%
• China: Customization of HMO blends for regional infant formula preferences. CAGR: 6.8%
• Germany: Expansion of medical nutrition using HMO-based therapeutics for gut microbiome and metabolic disorders. CAGR: 3.5%

Leading Suppliers

The HMO market is led by major biotech and nutrition companies such as:
• Chr. Hansen (Jennewein Biotechnologie) - Denmark/Germany
• BASF - Germany
• FrieslandCampina Ingredients - Netherlands
• Abbott Nutrition - USA
• dsm-firmenich (Glycom) - Denmark
• Nestlé Health Science - Switzerland

Specialized innovators like Inbiose, Kyowa Hakko Bio, ZuChem, and GlycoSyn are focusing on rare HMOs and scalable manufacturing methods, expanding applications in adult nutrition, dietary supplements, and functional foods.

Subscribe for Year-Round Insights → Stay ahead with quarterly and annual data updates! https://www.futuremarketinsights.com/reports/human-milk-oligosaccharides-market

Recent Industry Developments
• March 2024: DSM-Firmenich AG received USA and Australia regulatory approval for GlyCare 3-FL, enabling inclusion in functional foods and supplements.
• November 2024: Nestlé Health Science launched Wyeth Illume HMO-enriched milk in China, catering to premium infant nutrition demand.

Why FMI: https://www.futuremarketinsights.com/why-fmi

Browse Related Insights

Human Milk Oligosaccharides Market Share Analysis: https://www.futuremarketinsights.com/reports/human-milk-oligosaccharides-market-share-analysis

UK Human Milk Oligosaccharides Market: https://www.futuremarketinsights.com/reports/united-kingdom-human-milk-oligosaccharides-market

USA Human Milk Oligosaccharides Market: https://www.futuremarketinsights.com/reports/united-states-human-milk-oligosaccharides-market

Contact Us:

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware - 19713, USA
T: +1-347-918-3531
Website: https://www.futuremarketinsights.com

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

This release was published on openPR.